Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The Danish pharmaceutical company expects demand for obesity and diabetes drugs to rise, but forecasts sales growth to slow down this year. Read more.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Let's look deeper into these results and what they could mean for investors. Novo Nordisk's weight loss candidate in question ...

Novo Nordisk A/S investors got a much-needed boost ... The drugmaker’s shares jumped last Friday after its once-weekly shot of amycretin delivered as much as 22% weight loss in an early trial.

34,612 people played the daily Crossword recently. Can you solve it faster than others?34,612 people played the daily Crossword recently. Can you solve it faster than others?

The company's pipeline includes promising candidates such as Amycretin, an oral GLP-1/Amylin co-agonist that has shown competitive weight loss percentages in early trials. Novo Nordisk is also ...

The company's pipeline includes promising candidates such as Amycretin, an oral GLP-1/Amylin co-agonist that has shown competitive weight loss percentages in early trials. Novo Nordisk is also ...

We are proud to continue advancing innovations that will have a meaningful impact for this patient population, underscoring Novo Nordisk's commitment to cardiometabolic care." ...